Pathogen-Reduce Cryoprecipitate: An Overview of Method(s) in Pathogen Reduction, Transfusion-Transmitted Infection Risk, and Inventory Management Considerations.

Cryoprecipitated-AHF is a blood derivative produced from plasma donations. It is been used to treat Hemophilia A, von Willebrand disease, and congenital/acquired hypofibrinogenemia, and historically implicated with transmission of serious infectious diseases. As testing and treatment modalities have improved, treatment indications have narrowed considerable, but it still carries the highest potential risk of transfusion-transmitted infection (TTI). Pathogen-reduced cryoprecipitate availability has virtually eliminated the risk of pathogen transmission and extended the shelf-life to minimize waste in clinical practice. This article reviews methods of pathogen reduction, their effectiveness at reducing TTIs, and examine real-world experience of its implementation on inventory management.